Glucarpidase treatment significantly improves kidney recovery odds and reduces risks of neutropenia and transaminitis in MTX-AKI patients. The study utilized a target trial emulation framework to ...

Glucarpidase (Voraxaze, BTG International) also accelerated kidney recovery time and resulted in lower odds for other adverse events, including neutropenia and transaminitis. “Especially for ...